Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided cetuximab rechallenge with sintilimab and raltitrexed in RAS/BRAF wild-type metastatic colorectal cancer
ChiCTR2200066208Phase 2Not yet recruiting
- Sponsor
- Anhui Cancer Hospital
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, sintilimab and raltitrexed in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Anhui Cancer Hospital. Primary endpoint: Objective response rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
cetuximabsintilimabraltitrexed
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200066208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066208.